Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04166565
Title Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network

multiple myeloma


Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.